-
1
-
-
84898669547
-
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
-
Afdhal N, Reddy KR, Nelson DR., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93
-
(2014)
N Engl J Med
, vol.370
, pp. 1483-1493
-
-
Afdhal, N.1
Reddy, K.R.2
Nelson, D.R.3
-
2
-
-
84900339263
-
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
-
Afdhal N, Zeuzem S, Kwo P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98
-
(2014)
N Engl J Med
, vol.370
, pp. 1889-1898
-
-
Afdhal, N.1
Zeuzem, S.2
Kwo, P.3
-
3
-
-
84901044326
-
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
-
Ferenci P, Bernstein D, Lalezari J., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-92
-
(2014)
N Engl J Med
, vol.370
, pp. 1983-1992
-
-
Ferenci, P.1
Bernstein, D.2
Lalezari, J.3
-
4
-
-
84901036125
-
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
-
Poordad F, Hezode C, Trinh R., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-82
-
(2014)
N Engl J Med
, vol.370
, pp. 1973-1982
-
-
Poordad, F.1
Hezode, C.2
Trinh, R.3
-
5
-
-
84900326091
-
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
-
Kowdley KV, Gordon SC, Reddy KR., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88
-
(2014)
N Engl J Med
, vol.370
, pp. 1879-1888
-
-
Kowdley, K.V.1
Gordon, S.C.2
Reddy, K.R.3
-
6
-
-
84925607745
-
Virological response after 6 week triple-drug regimens for hepatitis C: A proof-of-concept phase 2A cohort study
-
Kohli A, Osinusi A, Sims Z., et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 2015; 385: 1107-13
-
(2015)
Lancet
, vol.385
, pp. 1107-1113
-
-
Kohli, A.1
Osinusi, A.2
Sims, Z.3
-
7
-
-
84939259594
-
Predictors of sustained viral response to 4-6 week duration therapy with ledipasvir + sofosbuvir + GS-9451 +/? GS-9669 in early and advanced fibrosis (NIH/UMD synergy trial)
-
Kattakuzhy S, Sidharthan S, Wilson EM., et al. Predictors of sustained viral response to 4-6 week duration therapy with ledipasvir + sofosbuvir + GS-9451 +/? GS-9669 in early and advanced fibrosis (NIH/UMD synergy trial). J Hepatology 2015; 62(S2): S669
-
(2015)
J Hepatology
, vol.62
, Issue.S2
, pp. S669
-
-
Kattakuzhy, S.1
Sidharthan, S.2
Wilson, E.M.3
-
8
-
-
84925362379
-
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: A randomised, doubleblind, phase 2 trial (SIRIUS)
-
Bourliere M, Bronowicki JP, De Ledinghen V., et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, doubleblind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015; 15: 397-404
-
(2015)
Lancet Infect Dis
, vol.15
, pp. 397-404
-
-
Bourliere, M.1
Bronowicki, J.P.2
De Ledinghen, V.3
-
9
-
-
84933181408
-
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials
-
Alqahtani SA, Afdhal N, Zeuzem S., et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology 2015; 62: 25-30
-
(2015)
Hepatology
, vol.62
, pp. 25-30
-
-
Alqahtani, S.A.1
Afdhal, N.2
Zeuzem, S.3
-
10
-
-
84919342996
-
Re-Treatment of chronic hepatitis C virus genotype 1 infection after relapse: An open-label pilot study
-
Osinusi A, Kohli A, Marti MM., et al. Re-Treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med 2014; 161: 634-8
-
(2014)
Ann Intern Med
, vol.161
, pp. 634-638
-
-
Osinusi, A.1
Kohli, A.2
Marti, M.M.3
-
11
-
-
84939256727
-
Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks
-
Lawitz E, Flamm S, Yang JC., et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. J Hepatology 2015; 62(S2): S192
-
(2015)
J Hepatology
, vol.62
, Issue.S2
, pp. S192
-
-
Lawitz, E.1
Flamm, S.2
Yang, J.C.3
-
12
-
-
84964762607
-
Long-Term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir
-
Dvory-Sobol H, Wyles D, Ouyang W., et al. Long-Term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J Hepatology 2015; 62(S2): S221
-
(2015)
J Hepatology
, vol.62
, Issue.S2
, pp. S221
-
-
Dvory-Sobol, H.1
Wyles, D.2
Ouyang, W.3
-
13
-
-
84964762303
-
Long-Term follow-up of treatmentemergent resistance-Associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens
-
Krishnan P, Tripathi R, Schnell G., et al. Long-Term follow-up of treatmentemergent resistance-Associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens. J Hepatology 2015; 62(S2): S220
-
(2015)
J Hepatology
, vol.62
, Issue.S2
, pp. S220
-
-
Krishnan, P.1
Tripathi, R.2
Schnell, G.3
-
14
-
-
77951083787
-
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
-
Poynard T, Lebray P, Ingiliz P., et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010; 10: 40
-
(2010)
BMC Gastroenterol
, vol.10
, pp. 40
-
-
Poynard, T.1
Lebray, P.2
Ingiliz, P.3
-
15
-
-
79952223130
-
Performance of the aspartate aminotransferaseto-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-Analysis
-
Lin ZH, Xin YN, Dong QJ., et al. Performance of the aspartate aminotransferaseto-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-Analysis. Hepatology 2011; 53: 726-36
-
(2011)
Hepatology
, vol.53
, pp. 726-736
-
-
Zh, L.1
Xin, Y.N.2
Dong, Q.J.3
-
16
-
-
84962296475
-
-
U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS Available at Accessed 19 October 2015
-
U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0. [Updated August 2009]. Available at: http: //rsc.tech-res.com/Document/safetyandpharmacovigilance/Table-for-Grading-Severity-of-Adult- Pediatric-Adverse-Events.pdf. Accessed 19 October 2015
-
Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0. [Updated August 2009]
-
-
-
17
-
-
84883089005
-
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: A randomized clinical trial
-
Osinusi A, Meissner EG, Lee YJ., et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310: 804-11
-
(2013)
JAMA
, vol.310
, pp. 804-811
-
-
Osinusi, A.1
Meissner, E.G.2
Lee, Y.J.3
-
18
-
-
84941917709
-
Hepatitis C virus drugs resistanceassociated substitutions: State of the art summary
-
Lontok E, Harrington P, Howe A., et al. Hepatitis C virus drugs resistanceassociated substitutions: state of the art summary. Hepatology 2015; doi: 10.1002/hep.27934
-
(2015)
Hepatology
-
-
Lontok, E.1
Harrington, P.2
Howe, A.3
-
19
-
-
84962316864
-
Four-week directly acting anti-HCV regimens in HCV genotype-1 patients without cirrhosis: A phase 2a cohort study
-
in press
-
Kohli A, Kattakuzhy S, Sidharthan S., et al. Four-week directly acting anti-HCV regimens in HCV genotype-1 patients without cirrhosis: a phase 2a cohort study. Ann Intern Med 2015; in press
-
(2015)
Ann Intern Med
-
-
Kohli, A.1
Kattakuzhy, S.2
Sidharthan, S.3
-
20
-
-
84959922676
-
Six-week combination directly acting anti-HCV therapy induces moderate rates of sustained virologic response in patients with advanced liver disease
-
Kattakuzhy S, Wilson EM, Sidharthan S., et al. Six-week combination directly acting anti-HCV therapy induces moderate rates of sustained virologic response in patients with advanced liver disease. Clin Infect Dis 2016; 62: 440-7
-
(2016)
Clin Infect Dis
, vol.62
, pp. 440-447
-
-
Kattakuzhy, S.1
Wilson, E.M.2
Sidharthan, S.3
-
21
-
-
84887460791
-
Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885
-
Wong KA, Worth A, Martin R., et al. Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother 2013; 57: 6333-40
-
(2013)
Antimicrob Agents Chemother
, vol.57
, pp. 6333-6340
-
-
Wong, K.A.1
Worth, A.2
Martin, R.3
-
22
-
-
84867674117
-
Antiviral activity and resistance profile of the novel HCV NS5A inhibitor GS-5885
-
Cheng G, Peng B, Corsa A., et al. Antiviral activity and resistance profile of the novel HCV NS5A inhibitor GS-5885. J Hepatology 2012; 56(S2): S464
-
(2012)
J Hepatology
, vol.56
, Issue.S2
, pp. S464
-
-
Cheng, G.1
Peng, B.2
Corsa, A.3
-
23
-
-
84929990886
-
Direct binding of ledipasvir to HCV NS5A: Mechanism of resistance to an HCV antiviral agent
-
Kwon HJ, Xing W, Chan K., et al. Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent. PLoS One 2015; 10: e0122844
-
(2015)
PLoS One
, vol.10
, pp. e0122844
-
-
Kwon, H.J.1
Xing, W.2
Chan, K.3
-
24
-
-
84921276609
-
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials
-
Svarovskaia ES, Dvory-Sobol H, Parkin N., et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 2014; 59: 1666-74
-
(2014)
Clin Infect Dis
, vol.59
, pp. 1666-1674
-
-
Svarovskaia, E.S.1
Dvory-Sobol, H.2
Parkin, N.3
-
25
-
-
84871814966
-
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
-
Gane EJ, Stedman CA, Hyland RH., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44
-
(2013)
N Engl J Med
, vol.368
, pp. 34-44
-
-
Gane, E.J.1
Stedman, C.A.2
Hyland, R.H.3
|